Independent data monitoring committees: Rationale, operations and controversies

Statistics in Medicine

Volumn 20, Issue 17-18, 2001, Pages 2573-2583

  Ellenberg, Susan S ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; NEW DRUG;

ARTICLE; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HUMAN; INFORMATION PROCESSING; PROFESSIONAL STANDARD; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS;

CLINICAL TRIALS; DRUG EVALUATION; HUMANS; RESEARCH DESIGN;

EID: 0035884169     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.730     Document Type: Article

References (39)

1. The NHLBI model: A twenty-five year history
2. Organization, review and administration of cooperative studies (Greenberg Report): A report from the Heart Special Project Committee to the National Advisory Heart Council, May 1967
3. Policies for study monitoring and interim reporting of results
4. Clinical trials and treatment effects monitoring
5. Comment
6. Comment
7. Comment
8. Comment
9. Comment
10. Comment
11. Comment
12. Comment
13. Some practical aspects of the interim monitoring of clinical trials
14. Monitoring of clinical trials: Issues and recommendations
15. The use of external monitoring committees in clinical trials of the National Institute of Allergy and Infectious Diseases
16. Masked monitoring in clinical trials-blind stupidity?
17. Data and safety monitoring in the Delta trial
18. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter
19. Data monitoring committees and capturing relevant information of high quality
20. A multiple testing procedure for clinical trials
21. Discrete sequential boundaries for clinical trials
22. Sequential methods based on the boundaries approach for the clinical comparison of survival times
23. Repeated assessment of results in clinical trials of cancer treatment
24. Comparison of Bayesian with group sequential methods for monitoring clinical trials
25. The what, why and how of Bayesian clinical trials monitoring
26. Stopping guidelines vs. stopping rules: A practitioner's point of view
27. When to stop a clinical trial
28. Informed consent: Protection or obstacle? Some emerging issues
29. ICH Harmonised tripartite guideline: Statistical principles for clinical trials. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use
30. Guideline for Industry: Good Clinical Practice
31. Guideline for Industry: Structure and Content of Clinical Study Reports
32. Repeated significance tests on accumulating data
33. Statistics: The problem of examining accumulating data more than once
34. Some FDA perspectives on data monitoring in clinical trials in drug development